Stock Events

Stock Events

Enliven Therapeutics 

$36.59
961
+$0.59+1.64% Wednesday 06:41

Statistics

Day High
36.59
Day Low
36.59
52W High
-
52W Low
-
Volume
100
Avg. Volume
-
Mkt Cap
2.17B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2025
Q4 2025
Next
-0.48
-0.43
-0.37
-0.32
Expected EPS
-0.461243
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-178.05MNet Income

Analyst Ratings

$50.50Average Price Target
The highest estimate is 56.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELVN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that operates in the same oncology space, competing directly with Enliven Therapeutics' cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including oncology, directly competing with Enliven Therapeutics.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has a broad range of oncology products that compete in the same market as Enliven Therapeutics' cancer treatments.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC has a strong focus on oncology, with a portfolio that competes with Enliven Therapeutics in developing cancer therapies.
Novartis
NVS
Mkt Cap297.32B
Novartis AG focuses on innovative healthcare solutions, including oncology, where it competes with Enliven Therapeutics in the cancer treatment space.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG, through its pharmaceuticals division, is a leader in oncology, directly competing with Enliven Therapeutics in cancer drug development.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is known for its strong presence in the oncology market, offering competitive therapies to those developed by Enliven Therapeutics.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. competes in the biopharmaceutical space, focusing on innovative therapies including oncology, which puts it in direct competition with Enliven Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is involved in the discovery and development of pharmaceutical products for the treatment of cancer, among other diseases, competing with Enliven Therapeutics.

About

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Show more...
CEO
ISIN
US29337E1029

Listings

ARCX
US
IMRA
BOATS
BOATS
ELVN.BOATS
XNAS
US
ELVN

0 Comments

Share your thoughts

FAQ

What is Enliven Therapeutics stock price today?▼
The current price of ELVN.BOATS is $36.59 USD — it has increased by +1.64% in the past 24 hours. Watch Enliven Therapeutics stock price performance more closely on the chart.
What is Enliven Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enliven Therapeutics stocks are traded under the ticker ELVN.BOATS.
What is Enliven Therapeutics market cap?▼
Today Enliven Therapeutics has the market capitalization of 2.17B
When is the next Enliven Therapeutics earnings date?▼
Enliven Therapeutics is going to release the next earnings report on May 20, 2026.
What were Enliven Therapeutics earnings last quarter?▼
ELVN.BOATS earnings for the last quarter are -0.48 USD per share, whereas the estimation was -0.39 USD resulting in a -24.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enliven Therapeutics revenue for the last year?▼
Enliven Therapeutics revenue for the last year amounts to 0 USD.
What is Enliven Therapeutics net income for the last year?▼
ELVN.BOATS net income for the last year is -178.05M USD.
When did Enliven Therapeutics complete a stock split?▼
Enliven Therapeutics has not had any recent stock splits.